Press Release

Giants of Cancer Care® Announces the 12th Annual Class of Inductees

The 15 inductees have been selected by their peers for their remarkable achievements in oncology research and clinical practice.

Giants of Cancer Care

Giants of Cancer Care

OncLive®, the nation’s leading multimedia resource for oncology professionals and Pfizer (platinum supporter) and Regeneron (silver supporter), are thrilled to announce the inductees of the 12th Annual Giants of Cancer Care recognition program.

The Giants of Cancer Care program aims to honor and celebrate the accomplishments of leading researchers and educators whose discoveries have propelled the field and set the groundwork for future advancements. Aselection committee of more than 115 esteemed oncologists choose honorees from a range of tumor types and specialized categories. The inductees have been selected by their peers for their remarkable achievements in oncology research and clinical practice. 

The awards ceremony will take place on Thursday, May 30, 2024, at 7 p.m. CDT at the Adler Planetarium in Chicago, Illinois. For more information on registration, click here.

“As we honor this year's inductees, I extend my congratulations to each and every one of them,” said Mike Hennessy Jr., president and CEO of MJH Life Sciences®, the parent company of OncLive. “Their remarkable dedication and contributions to the field of oncology have not gone unnoticed. Each one of them stands as a beacon of innovation and excellence within the global oncology community.”

This year’s inductees by award category are:

  • Breast Cancer: Joseph A. Sparano, M.D.–The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai
  • Community Outreach/Education: Edward S. Kim, M.D., MBA —City of Hope
  • Gastrointestinal Cancer: John L. Marshall, M.D. —The Ruesch Center for the Cure of Gastrointestinal Cancers/Georgetown University Lombardi Comprehensive Cancer Center
  • Genitourinary Cancer: Christopher J. Logothetis, M.D.—The University of Texas MD Anderson Cancer Center
  • Gynecologic Cancer: Carol A. Aghajanian, M.D.—Memorial Sloan Kettering Cancer Center
  • Leukemia: Guillermo Garcia-Manero, M.D.—The University of Texas MD Anderson Cancer Center
  • Lung Cancer: Solange Peters, M.D., Ph.D.— University Hospital of Lausanne, Switzerland
  • Lymphoma: Margaret A. Shipp, M.D. — Dana-Farber Cancer Institute/Harvard Medical School
  • Melanoma & Other Skin Cancers: Lynn M. Schuchter, M.D.—University of Pennsylvania Perelman School of Medicine/Abramson Cancer Center
  • Myeloma: Rafael Fonseca, M.D.—Mayo Clinic
  • Pediatric Oncology: Ching-Hon Pui, M.D.—St. Jude Children’s Research Hospital
  • Radiation Oncology: Ralph R. Weichselbaum, M.D.—The University of Chicago Medicine
  • Supportive, Palliative, and/or Geriatric Care: Ethan M. Basch, M.D., M.Sc.—Lineberger Comprehensive Cancer Center/University of North Carolina
  • Surgical Oncology: Kelly K. Hunt, M.D., FACS, FSSO— The University of Texas MD Anderson Cancer Center
  • Translational Science: Fabrice André, M.D., Ph.D.—Gustave Roussy (Villejuif, France)

In addition to the 2024 class of inductees noted above, OncLive and the Giants of Cancer Care Advisory Board have selected the third winner for the Michael J. Hennessy Visionary Award. The announcement of that winner will be made during the annual awards ceremony.

About OncLive 

The leading digital platform and multichannel resource for practicing oncologists, OncLive® offers oncology professionals peer-to-peer insights, news and practical information they can use to offer the best patient care. OncLive is a brand of MJH Life Sciences, the largest privately held, independent, full-service medical media company in North America dedicated to delivering trusted health care news across multiple channels.

About Giants of Cancer Care

Giants of Cancer Carecelebrates the achievements of leading researchers and educators whose discoveries have helped propel the field of oncology and established the building blocks for future advances. Every year, a selection committee of more than 120 eminent oncologists, researchers and clinicians chooses honorees from several types of tumor and specialty categories.

Media Contact:
Julia Paradizova
MJH Life Sciences